Skip to content Skip to footer
Subscribe Now
Viewpoints_Douglas E. Williams
VIEWPOINTS
PharmaShots Interview: Codiak BioSciences’ Douglas E. Williams Shares Insight on the Potential of its Engineered Exosomes
In an interview with PharmaShots, Douglas E. Williams, Ph.D., President and Chief Executive Officer of Codiak BioSciences shares insights on the potential of engineered exosomes and the data presented at SITC 2020. Shots: Codiak demonstrated the potential of engineered exosomes -  extracellular vesicles that act like the body's FedEx delivery trucks to carry messengers between cells -…
April 20, 20210Comments
Viewpoints_Dr. Kimberly Smith
VIEWPOINTS
PharmaShots Interview: ViiV Healthcare’s Dr. Kimberly Smith Shares Insight on the Data Presented at CROI 2021
In an interview with PharmaShots, Dr. Kimberly Smith, Head of Global Research and Medical Strategy at ViiV Healthcare shares insights on the clinical data of GSK3640254 (GSK'254) at CROI 2021. She also highlights the key points of P-IIIb ATLAS-2M study that provide further evidence for both the once-monthly and every 2-months dosing regimens of long-acting cabotegravir and…
April 19, 20210Comments
Viewpoints_Douglas Onsi
VIEWPOINTS
PharmaShots Interview: Leap Therapeutic’s Douglas Onsi Shares Insight on its Lead Candidate, DKN-01
In an interview with PharmaShots, Douglas Onsi, CEO and President of Leap Therapeutics shares insights on the clinical data of DKN-01 along with its mechanism. He also highlights the company's growth, plans, goal etc. Shots: DKK1 is a secreted protein that modulates cell signaling pathways known as the Wnt signaling pathways, as well as the PI3 kinase…
April 14, 20210Comments
Viewpoints_Tej Patel
VIEWPOINTS
PharmaShots Interview: Fluxergy’s Tej Patel Shares Insight on Multimodal Diagnostic System
In an interview with PharmaShots, Tej Patel, CEO of Fluxergy shared his views on Fluxergy's CE Marking and how it will democratize healthcare while creating better clinical outcomes. Shots: Fluxergy's One-hour COVID-19 test requires less than 2-3 minutes of hands-on time and provides lab-quality RT-PCR test results within an hour. The Fluxergy analyzer is a compact, high-density…
April 13, 20210Comments
Viewpoints_Dr. Gail McIntyre
VIEWPOINTS
PharmaShots Interview: Aravive’ s Dr. Gail McIntyre Shares Insight on AVB-500 and its Potential Against ccRCC
In an interview with PharmaShots, Dr. Gail McIntyre, CEO of Aravive shared her views on the AVB-500, its potential against ccRCC, and the design of the clinical trial evaluating the therapy. He also shed light on epidemiology of Clear Cell Renal Cell Carcinoma. Shots: AVB-500 is being evaluated in ccRCC, has been tested in preclinical models of…
April 9, 20210Comments
Viewpoints_Marc Meachem
VIEWPOINTS
PharmaShots Interview: Marc Meachem Shares Insight on the ViiV’s 2021 Commitment to the Community
In an interview with PharmaShots, Marc Meachem, Head of US External Affairs at ViiV Healthcare shared his views on the company's approach towards the community. He also shed light on the grants and funding received for the betterment of HIV patients. Shots: ViiV Healthcare is doubling its community investments in 2021 with the goal of disrupting the enduring…
April 7, 20210Comments
Viewpoints_Dietrich Stephan
VIEWPOINTS
PharmaShots Interview: NeuBase Therapeutics’ Dietrich Stephan Shares Insight on its Approach to Genetic Medicine
In an interview with PharmaShots, Dietrich Stephan, Ph.D., CEO of NeuBase Therapeutics shared his views on the importance of preclinical in vivo data for PATrOL-enabled anti-gene for myotonic dystrophy type 1. Shots: NeuBase announced in vitro and in vivo data for its DM1 program, demonstrating the potential of its genetic medicine platform to target the disease-causing…
April 6, 20210Comments

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]